Welcome to our dedicated page for Eyenovia news (Ticker: EYEN), a resource for investors and traders seeking the latest updates and insights on Eyenovia stock.
Eyenovia, Inc. (EYEN), which has adopted the corporate name Hyperion DeFi, Inc., generates news that spans both ophthalmic technology and digital asset markets. Company announcements describe a dual focus: development and commercialization of advanced topical eye treatments using its proprietary Optejet dispensing platform, and the build-out of a long-term strategic treasury of HYPE, the native token of the Hyperliquid blockchain.
On this news page, readers can follow updates on Eyenovia’s transition to Hyperion DeFi, including the reported name change and anticipated ticker change from EYEN to HYPD on the Nasdaq Capital Market. Releases detail the company’s private placement financing to acquire HYPE, launch of a co-branded Hyperliquid validator with Kinetiq, and broader onchain engagement strategy, including staking and validator operations supported by infrastructure provider Pier Two.
Investors and observers can also review ophthalmic-focused news, such as progress reports on the Optejet User Filled Device (UFD), verification and validation milestones, and plans for regulatory submissions. Additional items include updates on potential strategic transactions, such as a contemplated reverse merger with Betaliq, as well as information on existing FDA-approved products like clobetasol propionate ophthalmic suspension, 0.05% and Mydcombi for mydriasis.
Together, these news items provide insight into how the company is combining an ophthalmic technology platform with a cryptocurrency treasury reserve strategy centered on HYPE. For users tracking EYEN, this page offers a consolidated view of corporate actions, financing developments, product updates and blockchain-related initiatives described by the company in its press releases.
Eyenovia (NASDAQ: EYEN) announced its corporate rebranding to Hyperion DeFi, Inc., with its stock symbol changing to HYPD effective July 3, 2025. The rebranding reflects the company's strategic pivot from ophthalmic technologies to becoming a cryptocurrency-focused entity, specifically building a treasury reserve of HYPE tokens from the Hyperliquid protocol.
The company has launched its co-branded validator 'Kinetiq x Hyperion' and begun staking its HYPE holdings to generate yield. CEO Michael Rowe emphasized that the name Hyperion, inspired by the world's tallest living tree, symbolizes their ambition to become the largest HYPE token holder globally and develop the largest cryptocurrency-based treasury.
Eyenovia (NASDAQ: EYEN), a pioneer in ophthalmic technologies, has expanded its cryptocurrency holdings by purchasing an additional 265,872 HYPE tokens. This acquisition brings the company's total HYPE holdings to 1,306,452 tokens, acquired at an average price of $34.83 per token.
As the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, Eyenovia plans to use these holdings to support ecosystem growth initiatives, including validator operations and protocol-level yield generation opportunities.
Eyenovia (NASDAQ: EYEN), an ophthalmic technology company, has announced a partnership with Kinetiq to launch a co-branded Hyperliquid validator called 'Kinetiq x Hyperion'. This initiative follows Eyenovia's recent acquisition of 1,040,584.5 HYPE tokens, making it the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol.
The validator will be supported by Pier Two, an institutional staking services provider with SOC 2 Type I and II certifications. This collaboration represents Eyenovia's strategic move into onchain engagement, aiming to contribute to network stability while creating potential value through ecosystem participation.
Eyenovia (NASDAQ: EYEN) reports significant progress in developing its Optejet User Filled Device (UFD), targeting regulatory submission in Q4 2025. The device, designed for topical ophthalmic liquids including artificial tears and lens rewetting products, has successfully completed key verification and validation studies.
The completed parameters include physical requirements, usability testing, and dosing performance with precision within 1 microliter deviation. Notably, longevity testing demonstrated the device's capability to precisely dispense beyond 30,000 actuations. Safety testing, including electromagnetic interference and compatibility, has met all requirements according to IEC 60601 standards.
The company aims to submit a 510(k) application as early as September 2025, positioning the UFD Optejet to potentially double the usage efficiency of current eyedrop solutions.
Eyenovia (NASDAQ: EYEN) has entered into a non-binding letter of intent for a reverse merger with Betaliq, potentially creating a new publicly-listed eye care company. The merger would combine Betaliq's EyeSol® water-free drug delivery technology for glaucoma with Eyenovia's Optejet® dispensing platform.
The proposed transaction values Betaliq at approximately $77 million and Eyenovia at $15 million. Post-merger ownership would be split with Betaliq equity holders owning 83.7% and Eyenovia shareholders retaining 16.3% on a fully diluted basis.
The combined entity would continue marketing Eyenovia's FDA-approved products while leveraging the compatibility between EyeSol technology (featuring 10-microliter drop size) and the Optejet platform. The deal remains subject to due diligence, definitive agreements, board approvals, and financing contingencies.
Eyenovia (NASDAQ: EYEN) has successfully regained compliance with all Nasdaq Capital Market continued listing requirements, including the minimum bid price requirement rule (Rule 5550(a)(2)) and the low priced stocks rule (Rule 5810(c)(3)(A)(iii)). The compliance was achieved following a recently approved reverse stock split.
CEO Michael Rowe emphasized that maintaining the Nasdaq listing, combined with company restructuring efforts and accelerated development of the user-filled Optejet® device, represents significant milestones as they continue to explore strategic alternatives to maximize shareholder value.